Envoy Medical reports 12-month Acclaim cochlear implant trial data available

Envoy Medical, Inc. Class A

Envoy Medical, Inc. Class A

COCH

0.00
  • Envoy Medical posted 12-month data from the first 10 patients in its Acclaim fully implanted cochlear implant pivotal trial.
  • Mean CNC word recognition rose to 53.2% from 15.2% pre-implant, extending the 6-month score of 39.2%.
  • No serious adverse events were reported through 12 months in Stage 1.
  • Stage 2 is fully enrolled; 12-month data collection is expected by early Q2 2027, with an FDA PMA filing planned months later.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607140917NEWSFILECNPR____20260714_305014_1) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.